Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
Revenue of Arvinas, Inc. (ARVN)
Revenue in 2023 (TTM): $78.5 M
According to Arvinas, Inc.'s latest financial reports the company's current revenue (TTM) is $78.5 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Arvinas, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $78.5 M | $71.8 M | $-394,800,000 | $-363,900,000 | $-367,300,000 |
| 2022 | $131.4 M | $123.2 M | $-256,899,999 | $-251,000,000 | $-271,900,000 |
| 2021 | $46.7 M | $40.7 M | $-183,600,000 | $-191,000,000 | $-183,200,000 |
| 2020 | $21.8 M | $21.8 M | $-117,600,000 | $-119,332,064 | $-111,786,706 |
| 2019 | $42.98 M | $42.98 M | $-67,953,752 | $-70,292,227 | $-62,132,038 |
| 2018 | $14.32 M | $14.32 M | $-40,717,026 | $-41,480,466 | $-41,480,466 |
| 2017 | $7.58 M | $7.58 M | $-23,651,453 | $-24,049,206 | $-24,049,206 |
| 2016 | $6.67 M | $6.67 M | $-13,934,322 | $-14,438,051 | $-14,350,643 |